Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

Zongbi Yi(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(XinHua Hospital), Lifang Yuan(Cancer Hospital of Huanxing Chaoyang District Beijing), Haili Qian(Chinese Academy of Medical Sciences & Peking Union Medical College), Binliang Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunxiao Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Rongrong Chen, Xiaoying Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanfang Guan(Xi'an Jiaotong University), Lixi Li(Chinese Academy of Medical Sciences & Peking Union Medical College)
Scientific Reports
July 14, 2017
10.1038/s41598-017-06327-4
Cited by 30

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724